4//SEC Filing
TRANSKARYOTIC THERAPIES INC 4
Accession 0001104659-05-035143
CIK 0000885259operating
Filed
Jul 28, 8:00 PM ET
Accepted
Jul 29, 4:50 PM ET
Size
19.3 KB
Accession
0001104659-05-035143
Insider Transaction Report
Form 4
GILBERT WALTER PHD
Director
Transactions
- Disposition to Issuer
Stock Option (right to buy)
2005-07-27$4.31/sh−2,500$10,780→ 0 totalExercise: $32.69Exp: 2010-06-16→ Common Stock (2,500 underlying) - Disposition to Issuer
Stock Option (right to buy)
2005-07-27$1.00/sh−6,750$6,750→ 0 totalExercise: $36.00Exp: 2012-06-06→ Common Stock (6,750 underlying) - Disposition to Issuer
Common Stock
2005-07-27$37.00/sh−20,000$740,000→ 0 total(indirect: By Trust) - Disposition to Issuer
Stock Option (right to buy)
2005-07-27$22.39/sh−10,000$223,900→ 0 totalExercise: $14.61Exp: 2014-06-22→ Common Stock (10,000 underlying) - Disposition to Issuer
Common Stock
2005-07-27$37.00/sh−18,167$672,179→ 0 total
Footnotes (6)
- [F1]Disposed of pursuant to a merger agreement among the Issuer, Shire Pharmaceuticals Group plc and Sparta Acquisition Corporation, dated April 21, 2005, in exchange for the right to receive $37.00 per share.
- [F2]This option, which was granted on June 22, 2004 and provided for vesting in three approximately equal annual installments beginning on June 22, 2005, was cancelled in the merger in exchange for a cash payment of $223,900, representing the excess of $37.00 over the per share exercise price of the option multiplied by the number of shares subject to the option, whether vested or unvested.
- [F3]This option, which was granted on July 1, 2003 and provided for vesting in three approximately equal annual installments beginning on July 1, 2004, was cancelled in the merger in exchange for a cash payment of $259,200, representing the excess of $37.00 over the per share exercise price of the option multiplied by the number of shares subject to the option, whether vested or unvested.
- [F4]This option, which was granted on June 2, 2002 and provided for vesting in three equal annual installments beginning on March 6, 2003, was cancelled in the merger in exchange for a cash payment of $6,750, representing the excess of $37.00 over the per share exercise price of the option multiplied by the number of shares subject to the option, whether vested or unvested.
- [F5]This option, which was granted on June 14, 2001 and provided for vesting in three equal annual installments beginning on June 14, 2002, was cancelled in the merger in exchange for a cash payment of $45,225, representing the excess of $37.00 over the per share exercise price of the option multiplied by the number of shares subject to the option, whether vested or unvested.
- [F6]This option, which was granted on June 16, 2000 and provided for vesting in three approximately equal annual installments beginning on June 16, 2001, was cancelled in the merger in exchange for a cash payment of $10,780, representing the excess of $37.00 over the per share exercise price of the option multiplied by the number of shares subject to the option, whether vested or unvested.
Documents
Issuer
TRANSKARYOTIC THERAPIES INC
CIK 0000885259
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0000885259
Filing Metadata
- Form type
- 4
- Filed
- Jul 28, 8:00 PM ET
- Accepted
- Jul 29, 4:50 PM ET
- Size
- 19.3 KB